Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The study cohort will include all patients who initiate Tiotropium/ Olodaterol (Tio/Olo) or Tiotropium (Tio) during the patient selection period.
You may not be if
Aged \<40 years on cohort entry.
Any LAMA, LABA, or ICS maintenance therapy (alone or in combination) during the 180-day baseline period prior to cohort entry for maintenance treatment and duration \>30 days, or any prescription within the 30 days prior to cohort entry.
Patients without continuous enrolment (days since first inpatient/ outpatient encounter in the data) during the baseline period.
No prior diagnosis of COPD \[International Classification of Diseases (ICD)-10: J41\*, J43\*, J44\* and doubt (UTAGAIFLG) = 0 (no)\]
Patients without a second prescription claim of their index medication within 60 days after the cohort entry date.
Diagnosis of asthma \[ICD-10: J45\* and doubt (UTAGAIFLG) = 0 (no)\] during the baseline period.
Diagnosis of lung cancer \[ICD-10: C34\*, D02.2, Z80.1, Z85.1 and doubt (UTALAIFLG) = 0 (no)\] or lung transplant (Health claim code: 150317670, 150322510, 150322610, 150336510, 150336610, 150336710, 150399270) prior to the cohort entry date using all available data.
Patients who initiate both Tio/Olo and Tio simultaneously on the cohort entry date.
Any use of triple therapy (LAMA + LABA + ICS) during the baseline period or between the cohort entry date and 1 day prior to the start of follow-up.
